Cardiovascular outcomes under hypothetical blood‐pressure‐lowering intervention in type 2 diabetes: A target trial emulation
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70472 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Xue Tian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Antihypertensive Agents, Hypertension, Cardiovascular Diseases. Die Arbeit nennt 32 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
The effective target for systolic blood pressure (SBP) control in patients with diabetes was inconsistent. We evaluated the emulated effect of maintaining SBP below clinical thresholds on the risk of cardiovascular disease (CVD) and all‐cause mortality. Materials and Methods This study included 4264 patients with type 2 diabetes from the Kailaun study. We implemented the parametric g‐formula to simulate the hypothetical interventions on reducing SBP below 140, 130 and 120 mmHg over time, accounting for time‐varying confounding, reporting risk ratio (RR) and number needed to treat (NNT) for 10‐year risk of CVD and all‐cause mortality.
Results
Maintaining SBP below 140, 130 and 120 mmHg was associated with an 18%, 24%, and 31% relative risk reduction in the risk of CVD, with the RR (95% confidence interval [CI]) of 0.82 (0.75–0.88), 0.76 (0.69–0.86), and 0.69 (0.58–0.84), and the NNT of 32, 24, and 19, respectively, compared to no intervention. However, the benefits in reducing the risk of all‐cause mortality did not reach a significant level with maintaining SBP below 140 and 130 mmHg, with the RR (95% CI) of 0.98 (0.93–1.06) and 1.04 (0.95–1.12), respectively. The risk of all‐cause mortality significantly increased 15% with maintaining SBP ≤120 mmHg (RR, 1.15; 95% CI, 1.02–1.32). Subgroup analyses showed that maintaining SBP ≤120 mmHg tended to bring more harms than benefits in patients aged ≥60 years or without antihypertensive agents.
Conclusion
Among Chinese patients with type 2 diabetes, maintaining SBP ≤120 mmHg may not be an optimal target, in terms of the risk–benefit association of CVD and all‐cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Clinical Epidemiology and Clinical Trial, Capital Medical University, Beijing, China.
- Department of Epidemiology, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Kailuan Hospital, North China University of Science and Technology, Tangshan, China.
ORCID-Profile: Xue Tian, Shouling Wu, Xue Xia, Qin Xu, Anxin Wang
Zitieren
APA
Tian, X., Wu, S., Xia, X., Xu, Q., Chen, S., Wang, A., & Fang, R. (2026). Cardiovascular outcomes under hypothetical blood‐pressure‐lowering intervention in type 2 diabetes: A target trial emulation. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70472
Vancouver
Tian X, Wu S, Xia X, Xu Q, Chen S, Wang A, et al. Cardiovascular outcomes under hypothetical blood‐pressure‐lowering intervention in type 2 diabetes: A target trial emulation. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70472
BibTeX
@article{Tian2026,
author = {Tian, Xue and Wu, Shouling and Xia, Xue and Xu, Qin and Chen, Shuohua and Wang, Anxin and Fang, Ruile},
title = {Cardiovascular outcomes under hypothetical blood‐pressure‐lowering intervention in type 2 diabetes: A target trial emulation},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70472}
}
EUVIMED